CDTX vs MTD · rev $1.3M vs P/E 27, rev $3.87B
Cidara Therapeutics Inc (CDTX) versus Mettler-Toledo International Inc (MTD) — a side-by-side from cached financials, not a winner call.
Cidara Therapeutics Inc (CDTX) is a biotechnology company listed on US.
Mettler-Toledo International Inc (MTD) is a diagnostics & research company listed on NYSE.
Latest reported CDTX revenue for 2024-12-31 was $1.3M. Net income was -$169.8M. Revenue was down 94.5% from 2023-12-31 to 2024-12-31. CDTX currently screens at market cap $6.96B.
Latest reported MTD revenue for 2024-12-31 was $3.87B. Net income was $863.1M. Revenue was up 2.2% from 2023-12-31 to 2024-12-31. MTD currently screens at market cap $23.20B and trailing P/E 26.9.
CDTX currently screens at market cap $6.96B. MTD currently screens at market cap $23.20B and trailing P/E 26.9.
Not investment advice. Open the CDTX and MTD stock pages for the full models.
Not investment advice.